Neuronetics is trading 5% down today at $1.78 as risk-off sentiment toward smaller, loss-making medical device names weighs on the stock.
- The move continues a volatile downtrend fueled by prior clinical trial setbacks, negative cash flow, and a leveraged capital structure.
- Recent financial performance has been hampered by weakening margins and deteriorating balance sheet quality.
- No fresh company-specific news or analyst actions have emerged today to explain the current price action.